KIT V559G

CI-VAR-00004549Explore in graph →NP_000213.1:p.Val559GlyNM_000222.2:c.1676T>GClinVar 375912 CIViC 970 rs121913517

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor1
KIT V559G	Imatinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2458 Molecular models predict that deletion of a portion of the juxtamembrane domain relieves steric hindrance and results in higher binding affinity for imatinib. PMID 21364689 · Pierotti et al., 2011 · Open in CIViC	civic
Thymus Carcinoma1
KIT V559G	Imatinib Mesylate	Predictive	C	Supports Sensitivity Response	3	submitted	EID7357 A patient with a c-kit mutation-positive (V559G) thymic carcinoma received imatinib followed by sunitinib consecutively, and achieved long-term disease control for 27 months. PMID 27073655 · Hirai et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Thymus Squamous Cell Carcinoma1
KIT V559G	Sunitinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4116 An advanced thymic squamous cell carcinoma patient harboring a KIT V559G mutation was associated with partial response to sunitinib monotherapy. Upon identification of the KIT V559G mutation, the pat… (full text at CIViC) PMID 27073655 · Hirai et al., 2016 · Open in CIViC	civic